Navigation Links
Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
Date:12/3/2007

TUSTIN, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its financial results for the second quarter of fiscal year 2008 on December 10, 2007 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST on the same day.

Peregrine's senior management will discuss financial results for the quarter and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

The conference call and webcast will begin at 11:30 a.m. EST/8:30 a.m. PST.

To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through December 17, 2007 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatme
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...-ShanghaiBiolaxyannouncedthe,ChineseStateFood&...onalnewdrugapplication(IND)foritsoralinsulinprojec...abetes.ThisIND,approvalallowsBiolaxytoinitiateitsf...rcharacteristicofhighbloodglucoseandpoor,metabolis...ro-and,macro-vasculardiseases,lossofvision,kidneyf...
(Date:11/24/2009)...forpatientswithadvanced-stage,orrecurrentendometri...tCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ)(...edonendocrinetherapyandoncology,todayannouncedposi...otoxicpeptideconjugate,AEZS-108(formerlyAN-152),in...napersonalizedhealthcareapproach,thestudyselectedp...
(Date:11/24/2009)...irstCall/--ArenaPharmaceuticals,Inc.(Nasdaq: ARNA ...tatthePiperJaffray21stAnnualHealthCareConferenceon...icTime)attheNewYorkPalaceHotelinNewYorkCity.JackLi...heduledtoprovideanoverviewofthecompany,includingit...iveaudiowebcastofthepresentationwillbeavailableund...
(Date:11/24/2009)...s Customers with Partners Validated to Process and...ts , Ottawa, ON (PRWEB) N...der of products for biological sample collection, ... new global partner program. The program offers si...ommunity and is designed to help partners scale an...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...ord of Investment Success -, GAITHERSBURG, Md., J...rldwide biologics unit of AstraZeneca plc (LSE: AZ...uccessful venture capital fund,MedImmune Ventures,...gic,interest to both organizations by adding the t...isease, pain and central nervous system,disorders ...
...Jan. 7 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-T... that: Xinjiang,Corps Agro-technology Extended Ter...lizer products "Pen Duo Shou" and "Jin Peng Jia Ba...The new official fertilizer,certificate replaces t...egistration Certificate., In 2007, Xinjiang Corps...
...gland, January 7 /PRNewswire-FirstCall/,-- Evotec ... that it has,successfully completed a Phase I safe...inary results confirm the good tolerability profil...her clinical development., EVT 302, a reversible ...ment for smoking cessation, was investigated in an...
Other Biology Technology:MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 3Kiwa Fertilizers Pass Independent Tests 2Kiwa Fertilizers Pass Independent Tests 3Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 2Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 3Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 4Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 5
(Date:11/23/2009)...TORONTO, November 23, 2009 - The time of day matte... to a new paper produced by a research team led by... Scarborough,s vice-principal for research and col...ogy at the St. George campus. , Capitalizing o...poplar tree, the research team examined how poplar...
(Date:11/23/2009)...CHAMPAIGN, Ill. A new study provides "incontrover...f Toba on the island of Sumatra about 73,000 years...miles from the epicenter, researchers report. , ...ers of ash into the atmosphere, leaving a crater (... kilometers long and 35 kilometers wide. Ash from ...
(Date:11/23/2009)..., BIRMINGHAM, Ala. A new study by University of A...body-mass index (BMI) and co-existing medical cond... survival observed among African-Americans compare...udy is published online Nov. 23 in Cancer , a jou...ng indicates that although BMI and co-morbidity ar...
Breaking Biology News(10 mins):Time of day matters to thirsty trees, U of T researcher discovers 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Pelosi Statement on Senate Health Insurance Reform Bill 61677 1Opto electronic nose sniffs out toxic gases 14911 1Opto electronic nose sniffs out toxic gases 14911 2Opto electronic nose sniffs out toxic gases 14911 3Universal Health Services Inc Announces Stock Split and Cash Dividend Increase 61672 1
...s from infectious diseases in hurricane-devastated...ommon infections rather than exotic diseases. Thes...imple hygiene measures and a little common sense. ...e unlikely to break out after hurricanes and flood...urally occur," says Ruth Berkelman, MD, Chair of t...
...scovery that will advance our understanding of how...st cancer cells. The research, in collaboration wi...ues de Montreal (IRCM) identifies 153 genes that r...be used to halt the growth of breast cancer cells....e National Academy of Sciences (PNAS), will focus ...
...ur finger on a hot stove? Imagine what it,s like t... the time and know there,s virtually nothing you c...d it,s a common complication of many diseases and ...e little effect on this type of pain, which is cau...n, temperature and touch signals to and from the b...
Other Biology News:Hurricane aftermath: Infectious disease threats from common, not exotic, diseases 2Scientists discover genetic pathway responsible for breast cancer cell growth 2Scientists use gene transfer technology and common virus to block neuropathic pain 2Scientists use gene transfer technology and common virus to block neuropathic pain 3Scientists use gene transfer technology and common virus to block neuropathic pain 4
Rabbit Anti-HES1 Antibody, Unconjugated from ABR-Affinity BioReagents
Rat Anti-Mouse Endoglin Monoclonal Antibody, Fluorescein Conjugated, Clone 209701 from R&D Systems
Caspase Inhibitor Ac-DEVD-CHO, Unconjugated from Promega
Coriolis equipment from Bertin Technologies
Biology Products: